Taysha Gene Therapies
56 articles about Taysha Gene Therapies
-
Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposium
2/9/2022
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), today announced the presentation of clinical safety data supporting the first-generation construct at the highest dose of 1.0x1015 total vg for the treatment of CLN7 Batten disease at the 18th Annual WORLD Symposium.
-
Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy
1/31/2022
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), today reported positive clinical efficacy and safety data for the high dose cohort of 3.5x1014 total vg, as well as long-term durability data across all therapeutic doses of TSHA-120 in giant axonal neuropathy (GAN).
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
Taysha said the data for TSHA-101 is the “first-ever to support the bicistronic vector approach in humans delivering both HEXA and HEXB genes in the endogenous ratio.”
-
Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101
1/27/2022
Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in Clinical Development, Demonstrating Normalization of β -Hexosaminidase A Enzyme Activity in Patients With GM2 Gangliosidosis.
-
Taysha Gene Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/6/2022
Taysha Gene Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference.
-
Taysha Gene Therapies to Participate in Panel Discussions at the LifeSci Partners 11th Annual Corporate Access Event
1/3/2022
Taysha Gene Therapies to Participate in Panel Discussions at the LifeSci Partners 11th Annual Corporate Access Event.
-
Taysha Gene Therapies Announces January 2022 Virtual Investor Events to Review Preliminary Clinical Data for TSHA-101 in GM2 Gangliosidosis and High Dose Cohort and Long-Term Clinical Data for TSHA-120 in Giant Axonal Neuropathy
12/28/2021
Taysha Gene Therapies, Inc. today announced plans to provide clinical data updates, including its intent to host two virtual investor conference calls and webcasts in January 2022.
-
Taysha Gene Therapies Added to the ICE Biotechnology Index
12/23/2021
Taysha Gene Therapies, Inc. today announced that it has been added to the ICE Biotechnology Index (NYSE:ICEBIO) in accordance with the annual reconstitution of the index, effective prior to the U.S. market open on Monday, December 20, 2021.
-
Taysha Gene Therapies Announces Positive Preliminary Clinical Safety Data For First-Generation Construct In CLN7 Disease and Completion of Next-Generation CLN7 Construct Design
12/22/2021
Taysha Gene Therapies, Inc. today announced preliminary clinical safety data for the first-generation construct in CLN7 disease.
-
Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-118 for the Treatment of CLN1 Disease
12/16/2021
Taysha Gene Therapies, Inc. (Nasdaq: TSHA),, today announced the initiation of clinical development of TSHA-118 for the treatment of CLN1 disease under a recently approved Clinical Trial Application (CTA).
-
Taysha Gene Therapies Added to the Nasdaq Biotechnology Index
12/15/2021
Taysha Gene Therapies, Inc. today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI) in accordance with the annual reconstitution of the index, effective prior to the U.S. market open on Monday, December 20, 2021.
-
Taysha Gene Therapies Announces Late-Breaking Abstract and Poster Presentation on Positive Preclinical Data For TSHA-105 Demonstrating Therapeutic Potential for the Treatment of Epilepsy Caused by SLCA13A5 Deficiency
12/6/2021
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), today announced a late-breaking abstract and poster presentation by Dr. Rachel Bailey, Assistant Professor at UT Southwestern Medical Center on positive preclinical data for TSHA-105.
-
Taysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/10/2021
Taysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-
Taysha Gene Therapies to Participate in Upcoming November Investor Healthcare Conferences
11/8/2021
Taysha Gene Therapies, Inc. today announced its participation in the following events: Stifel 2021 Virtual Healthcare Conference on November 15, 2021 at 11:20 am ET Jefferies London Healthcare Conference November 17, 2021 at 12:20 pm GMT 4th Annual Evercore ISI HealthCONx Virtual Conference on November 30, 2021 at 4:20 pm ET
-
Collaboration is key to faster breakthroughs. The NIH, FDA, and 15 private organizations have announced they are joining forces for the sake of the 30 million Americans suffering from a rare disease.